Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » RISKS RELATING TO THE BUSINESS

This excerpt taken from the EYE 10-K filed Mar 3, 2008.

Risks Relating to Our Business

STYLE="margin-top:6px;margin-bottom:0px">We may not successfully make or integrate acquisitions or enter into strategic alliances.

STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%">As part of our business strategy, we intend to pursue selected acquisitions and strategic alliances and partnerships. We compete with other ophthalmic
surgical product and eye care companies, among others, for these opportunities and we cannot assure you that we will be able to effect strategic alliances, partnerships or acquisitions on commercially reasonable terms or at all. Even if we do enter
into these transactions, we may experience:

 







 • 

delays in realizing the benefits we anticipate, or we may not realize the benefits we anticipate at all;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







 • 

difficulties in integrating any acquired companies and products into our existing business;

STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> 







 • 

attrition of key personnel from acquired businesses;

 







 • 

costs or charges to expand the operations of these acquired entities or otherwise for which such investment may not provide an adequate return;

 







 • 

difficulties or delays in obtaining regulatory approvals;

 







 • 

the expenditure of significant and material monies to complete integration work for these acquired entities as well as significantly higher costs of integration
than we anticipated; or

 







 • 

unforeseen operating difficulties that require significant financial and managerial resources that would otherwise be available for the ongoing development or
expansion of our existing operations.

Consummating these transactions could also result in the incurrence of additional
debt and related interest expense, as well as unforeseen contingent liabilities, all of which could have a material adverse effect on our business, financial condition and results of operations. We may also issue additional equity in connection with
these transactions, which may dilute our existing stockholders.

This excerpt taken from the EYE 10-Q filed Apr 29, 2005.

RISKS RELATING TO THE BUSINESS

 

  •   Uncertainties associated with the research and development and regulatory approval processes;

 

  •   Our ability to make and integrate acquisitions or enter into strategic alliances;

 

  •   Exposure to risks associated with doing business outside of the United States, where we conduct a significant amount of our sales and operations;

 

  •   Foreign currency risks and fluctuation in interest rates;

 

  •   Our ability to introduce new commercially successful products in a timely manner;

 

  •   Our ability to transition our manufacturing operations for products formerly supplied by Allergan;

 

  •   Our ability to maintain a sufficient and timely supply of products we manufacture;

 

  •   Our reliance on sole source suppliers for raw materials and other products;

 

  •   Intense competition from companies with substantially more resources and a greater marketing scale;

 

  •   Risks and expenses associated with our ability to protect our intellectual property rights;

 

  •   Risks and expenses associated with intellectual property litigation and infringement claims;

 

  •   Unexpected losses due to product liability claims, product recalls or corrections, or other litigation;

 

  •   Our ability to maintain our relationships with health care providers;

 

  •   Risks, uncertainties and delays associated with extensive government regulation of our business, including risks associated with regulatory compliance, quality systems standards, and complaint-handling;

 

  •   Our ability to attract, hire and retain qualified personnel;

 

  •   Risks associated with indemnification obligations and potential tax liabilities associated with our spin-off from Allergan;

 

  •   Our significant debt, which contains covenants limiting our business activities; and

 

19

Table of Contents
  •   The impact of a change in the accounting treatment of stock options or other significant changes to generally accepted accounting principles.

 

EXCERPTS ON THIS PAGE:

10-K
Mar 3, 2008
10-Q
Apr 29, 2005

RELATED TOPICS for EYE:

"RISKS RELATING TO THE BUSINESS" elsewhere:

AtriCure (ATRC)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki